The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ARA, INVVY and S

The Gross Law Firm


The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ARA, INVVY and S

Friday, May 17, 2019 12:45 PM

NEW YORK, NY / ACCESSWIRE / May 17, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

American Renal Associates Holdings, Inc. (NYSE: ARA)

Investors Affected : August 10, 2016 - March 27, 2019

A class action has commenced on behalf of certain shareholders in American Renal Associates Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission ("SEC") investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/american-renal-associates-holdings-inc/?id=1561&from=1.

Indivior PLC (OTCMKTS: INVVY)

Investors Affected : March 10, 2015 - April 9, 2019

A class action has commenced on behalf of certain shareholders in Indivior PLC. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/indivior-plc/?id=1561&from=1.

Sprint Corporation (NYSE: S)

Investors Affected : January 31, 2019 - April 16, 2019

A class action has commenced on behalf of certain shareholders in Sprint Corporation. The complaint alleges that Sprint made materially false and misleading statements and/or failed to disclose material information. In particular, the complaint alleges that throughout the class period Sprint misrepresented the number of net postpaid subscriber additions in its Form 10-Q for the period ending December 31, 2018. Sprint would later admit that the data was "incomplete," and "not a substitute for a realistic analysis of the key factors that are most probative of Sprint's overall competitive position and prospects," because "postpaid net additions recently have been driven by 'free lines' offered to Sprint customers and the inclusion of less valuable tablet and other non-phone devices, as well as pre to post migrations that do not represent 'new' Sprint customers."

Shareholders may find more information at https://securitiesclasslaw.com/securities/sprint-corporation/?id=1561&from=1.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm


SHARE ARTICLE